REGN stock forecast, quote, news & analysis

Key Takeaways

• Regeneron Pharmaceuticals (REGN) declined roughly 13.7% over the last 30 days, falling from $852.03 to $735.20 per share.
• The pullback followed a run-up to a 52-week high of $852.03 in early September, triggering profit-taking after a multi-month rally.
• The October 1 expansion of Regeneron's Sanofi alliance, carrying a $1 billion upfront payment and up to $7 billion in milestones, was read by investors as diluting economics on its next-generation immunology pipeline without improving existing Dupixent profit-sharing terms.
• Despite the recent slide, the stock remains up approximately 12.4% over the trailing three-month period.
• Wall Street stayed constructive, with Argus upgrading the stock to Buy at an $850 target and consensus estimates clustering near $851.

Regeneron Pharmaceuticals (REGN) Company Overview and Market Position

Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases across ophthalmology, immunology and inflammation, oncology, cardiovascular and metabolic conditions, and rare disorders. Its largest franchises include EYLEA and EYLEA HD (aflibercept) for retinal diseases and Dupixent (dupilumab), developed and commercialized with partner Sanofi (SNY), for diseases driven by type 2 inflammation. Libtayo (cemiplimab) anchors its oncology business, while EYLEA is also marketed outside the United States with Bayer (BAYRY). Regeneron builds its pipeline on proprietary VelociSuite antibody technologies and data from the Regeneron Genetics Center, which is why investors closely track its product momentum, pipeline readouts, and collaboration economics.

Regeneron Pharmaceuticals (REGN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Regeneron shares fell from a closing price of $852.03 on September 2 to $735.20, a decline of approximately 13.7%. The stock had reached its 52-week high of $852.03 in early September before drifting lower through the month, ending September at $758.27. The announcement of the expanded Sanofi alliance on October 1 accelerated the move, with shares closing around $735.20 in the following session.

The longer-term picture remains more mixed. Over the trailing quarter, Regeneron is still up about 12.4%, having climbed from roughly $654 in early July to its early-September peak before the recent retracement. The 30-day weakness therefore represents a sharp, near-term correction within a still-positive multi-month trend.

What Drove REGN Stock Price in the Last 30 Days

The dominant catalyst was the October 1 announcement that Regeneron and Sanofi would expand their long-running immunology collaboration. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments for four next-generation, long-acting antibodies, including REGN20423, a Phase 1 IL-13 antibody, with the remaining programs expected to enter the clinic in 2027. The companies will share development and commercialization costs and split future profits 50:50, while existing Dupixent profit-sharing terms remain unchanged.

The market interpreted these terms cautiously. Because Regeneron ceded half the economics on its next-generation pipeline without securing more favorable Dupixent terms, the stock reversed early gains and closed lower. Prior to that news, the shares had already been consolidating after the strong summer rally, reflecting profit-taking and a shift in sentiment across the biopharma sector. Technically, Regeneron traded below its 20-day and 50-day moving averages with an RSI in the mid-30s, while options positioning leaned defensive.

What Drove REGN Stock Performance Over the Last Quarter

The trailing quarter told a broader growth story. Regeneron's second-quarter 2026 results, reported in late July, showed double-digit year-over-year revenue and earnings growth, with EYLEA HD growing 27% sequentially to represent roughly 60% of total EYLEA franchise U.S. sales. Dupixent, annualizing near $24 billion, and Libtayo each reached record quarterly net sales. The company also repaid its Sanofi development balance during the quarter, a move expected to lift collaboration revenue beginning in the third quarter.

These fundamentals, combined with a series of regulatory approvals, supported the rally from the low-$650s into the $850s before the recent pullback. The last-quarter gain of about 12.4% reflects strong operating momentum that was partially unwound by the September correction and the Sanofi announcement.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a platform that offers hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a streamlined way to review strategies that are currently standing out. These bots vary in strategy, timeframe, and performance metrics, so investors can evaluate approaches that align with their own objectives and risk tolerance. Browsing the page offers a practical starting point for those exploring how AI-driven signals can complement a broader research process.

REGN Stock Forecast Drivers: What Investors Should Watch Next

Several catalysts will shape Regeneron's near-term trajectory. The pending FDA decision on the EYLEA HD pre-filled syringe, which the company targets for year-end, is a key commercial milestone, as are continued EYLEA HD demand trends in the face of EYLEA 2 mg biosimilar competition. Investors will also watch the third-quarter earnings report for evidence of the expected step-up in Sanofi collaboration revenue following the development-balance repayment.

Pipeline events include a November PDUFA date for cemdisiran in generalized myasthenia gravis and additional readouts across the complement, oncology, and metabolic programs. Competitive dynamics in the anti-VEGF category, including Roche (RHHBY) Vabysmo, and the execution of the expanded Sanofi collaboration will remain important variables for sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations